Nurami Medical
Modernizing Soft Tissue Repair
Startup B Health Tech & Life Sciences Est. 2014
Total Raised
$43.65M
B
Last Round
$30M
9 rounds
Investors
11
11 public
Team
3
11-50 employees
Confidence
99/100
News
8
articles
Patents
1
About
Nurami harnesses nanofibers and novel biomaterials to modernize soft tissue surgical repair. Nurami’s proprietary, electrospun-based platform technology enables the creation of an innovative category of bio surgical implants to seal and heal wounds effectively. These advanced products address complications associated with current soft tissue implants, such as dangerous leaks, and promote healthy tissue formation such as Dura repair as well as other tissue recovery processes. Nurami's first soft-tissue repair product, ArtiFascia, is a multilayer, Dural repair graft made of biocompatible and bioabsorbable polymers with integrated barrier layer and a biomimetic structure of electrospun fibers designed to promote neodura regeneration. ArtiFascia is available for commercial use in the USA and has FDA 510(k) clearance.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringMedical DevicesMedical Treatment & Therapeutics
Core Technology
Materials & SubstancesNanomaterialsPolymersImplants
Target Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesBiotechnology
Business Model
B2B
Tags
surgeonsbiodegradablenanotechnologysurgeryneurologydoctorshospitalsmedical-technologiesregenerative-medicinefibersneurosurgerylife-sciencesmedical-devicesbiotechnologybiomaterialstissue-regeneration
Funding & Events
Nov 2020
B Round $6M
Almeda Ventures (Lead), GlenRock Group, Ratio Technologies
Mar 2025
Undisclosed Round $30M
NGT HealthCare II, Iron Nation
Jul 2024
Non-equity $2.69M
EIC Accelerator, Iron Nation
Jul 2018
A Round $2M
Beijing Jishi Daze Biological Science & Technology Center, Zhongguancun Translational Medicine Science & Technology, Beijing BASIBA Biomedical Engineering Science & Technology Development Co.
Jan 2024
SAFE Undisclosed
Iron Nation
Dec 2019
Non-equity $350K
Israel Innovation Authority
Dec 2018
Non-equity $375K
Israel Innovation Authority
Dec 2017
Non-equity $490K
Israel Innovation Authority
Dec 2016
Seed $1.74M
Office of the Chief Scientist, AMIT-Technion ( The Alfred Mann Institute), NGT3
News (8)
Mar 2, 2025 · www.calcalistech.com
growth-positive
The woman behind the billion-dollar brain surgery breakthrough | CTech
InvestmentExpandFDA approved/pending approval
Aug 21, 2023 · www.prnewswire.com
growth-positive
Nurami Medical's ArtiFascia® Dura Substitute Receives FDA Clearance
Customers
May 30, 2022 · finance.walla.co.il
Growth-Positive
היישר מגונסון & גונסון: פיטר סטבינס מונה ליו"ר נוראמי מדיקל - וואלה! כסף
Management ChangesExpand
Jan 27, 2022 · en.globes.co.il
growth-positive
Nurami seeks FDA, EU approval for soft tissue repair solution
Investment
Oct 24, 2021 · bloomer.co.il
growth-positive
אלמדה ונצ'רס מודיעה על השלמת אבן דרך בחברת פורטפוליו בלומר
Investment
Nov 2, 2020 · www.prnewswire.com
growth-positive
Nurami Medical Raises up to $6 Million Round in Series B Funding Led by Almeda Ventures
Investment
Jul 16, 2019 · www.israel21c.org
growth-positive
Revolutionary patch keeps brain safe after cranial surgery
Customers
Jan 1, 2017 · www.timesofisrael.com
growth-positive
Israeli biotechnology startup Nurami Medical raises NIS 2.5m
Investment
Details
Product Stage
Clinical Trial
Employees
11-50
Exact Count
28
District
North District
Founded
2014
Registrar
515038594
Crunchbase
nurami-medical
Locations
Ha-Namal Street 36, Haifa, Israel
Links
Website
LinkedIn
Facebook
Careers
Admin
Last Update
Jul 7, 2025
Verified by
Sharon Shapira
Claimed
Yes
Missing
markets
Team (3)
Hannoch Marksheid
CEO
Amir Bahar
Co-Founder, COO & Clinical Director
Founder
Nora Nseir
Co-founder, Inventor, BOD, R&D Director
Founder
Internal
Created by
Jenny Sotnik-Talisman (genys30@yahoo.com)
Created
2014-10-04T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)